Fosmanogepix

Summary

Fosmanogepix (CHEMBL4297591) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including candidemia and candidiasis, invasive.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 9
• Chemistry: 468.4 Da · C22H21N4O6P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297591
Name	Fosmanogepix
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	44123754
Molecular formula	C22H21N4O6P
Molecular weight	468.4
InChIKey	JQONJQKKVAHONF-UHFFFAOYSA-N

SMILES: C1=CC=NC(=C1)OCC2=CC=C(C=C2)CC3=NOC(=C3)C4=C([N+](=CC=C4)COP(=O)(O)[O-])N

IUPAC name: [2-amino-3-[3-[[4-(pyridin-2-yloxymethyl)phenyl]methyl]-1,2-oxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate

Also known as: Apx-001, Apx001, APX001, E1211, Fosmanogepix, FOSMANOGEPIX

Patent coverage: 35 distinct patent families (62 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
candidemia	3	MONDO:0044070	EFO:1001282
candidiasis, invasive	3	MONDO:0044067	EFO:1001283
fungal infectious disease	2	MONDO:0002041	MONDO:0002041
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
liver disorder	1	MONDO:0005154	EFO:0001421
fungal lung infectious disease	1	MONDO:0005766	EFO:0007278

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05421858	PHASE3	RECRUITING	A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT06925321	PHASE3	RECRUITING	A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT03604705	PHASE2	COMPLETED	An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
NCT04148287	PHASE2	COMPLETED	An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
NCT04240886	PHASE2	TERMINATED	Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
NCT04166669	PHASE1	COMPLETED	A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
NCT05491733	PHASE1	COMPLETED	A Bioequivalence Study of APX001 High-load and Low-load Tablets
NCT05582187	PHASE1	COMPLETED	A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
NCT06961708	PHASE1	COMPLETED	A Study of Fosmanogepix in Healthy Adult Chinese Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).